Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers

• Published in: Arzneimittel-Forschung Vol. 52; no. 9; p. 689
• Main Authors: Cooper, Mark, Sologuren, Ander, Valiente, Roman, Smith, Jeffery
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2002
• Subjects: Administration, Oral; Adolescent; Adult; Antiemetics - administration & dosage; Antiemetics - pharmacology; Benzimidazoles - administration & dosage; Benzimidazoles - pharmacology; Dose-Response Relationship, Drug; Emetics; Granisetron - pharmacology; Humans; Injections, Intravenous; Ipecac; Male; Nausea - chemically induced; Nausea - prevention & control; Piperidines - administration & dosage; Piperidines - pharmacology; Receptors, Serotonin - drug effects; Receptors, Serotonin, 5-HT3; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - pharmacology; Time Factors; Vomiting - chemically induced; Vomiting - prevention & control

The purpose of these studies was to evaluate the effect of lerisetron (1-phenyl-methyl-2-piperazinyl-1H-benzimidazole hydrochloride, CAS 143257-98-1, F-0930-RS2), a new 5-HT3 receptor antagonist, on ipecacuanha-induced nausea and vomiting. The ipecacuanha model of emesis has been used to test the an...